Tools for Practice Outils pour la pratique

#319 Should a ‘flozin’ be chosen? Part 2: SGLT2 inhibitors in patients with chronic kidney disease

What are the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on patient-relevant outcomes in chronic kidney disease (CKD)?

For every 100 patients with CKD treated with an SGLT2i for 5 years, ~3-4 fewer will develop end-stage kidney disease (ESKD) and ~3-4 fewer will die from any cause compared to placebo. Sotagliflozin is not better than placebo for these outcomes

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • Two systematic reviews of relevant randomized, placebo-controlled trials (RCTs) included patients with CKD.1,2 Results statistically different unless noted.
    • 52,827 patients with various cardiovascular/CKD risk. Of those with CKD, at 5 years:1
      • ESKD: 8.9% versus 12% (placebo), number needed to treat (NNT)=33.
      • Cardiovascular death: 11% versus 14% (placebo), NNT=27.
      • Overall mortality: 19% versus 22% (placebo), NNT=31.
    • 8 RCTs, 26,106 patients with baseline CKD, at 2.5 yrs:2
      • Cardiovascular disease: 10% versus 11% (placebo), NNT=91.
      • Composite kidney outcome (40-60% eGFR decline, ESKD, or renal death): 4.8% versus 6.9% (placebo), NNT=48.
    • Limitations: Included RCTs not specific to CKD patients.
  • Three industry-funded RCTs3,4,5 specific to CKD patients (neither above review included all 3 in every outcome). Mean eGFR~40-55ml/min/1.73m2, albumin-to-creatinine ratio ~75-105mg/mmol, 67-100% had diabetes.
    • CREDENCE:3 4,401 patients, canagliflozin 100mg daily. At 2.6 years:
      • ESKD: 5.3% versus 7.5% (placebo), NNT=45.
      • Cardiovascular death: 5.0% versus 6.4% (placebo), NNT=71.
      • All-cause mortality: 7.6% versus 9.1% (placebo), NNT=67.
    • DAPA-CKD:4 4,304 patients, dapagliflozin 10mg daily. At 2.4 years:
      • ESKD: 5.1% versus 7.5% (placebo), NNT=42.
      • Cardiovascular death: 3.0% versus 3.7% (placebo), not statistically different.
      • All-cause mortality: 4.7% versus 6.8% (placebo), NNT=48.
    • SCORED:5 10,584 patients, sotagliflozin 200-400mg daily. At 1.3 years:
      • No difference in composite kidney outcome, cardiovascular death, or all-cause mortality.
    • Adverse events:3-5
      • Increase in genital infections [number needed to harm (NNH) 59-67], volume depletion (NNH=59-77), and DKA (NNH=220 to not statistically significant).
  • One meta-analysis of DAPA-CKD and CREDENCE only. At ~2.5 years:6
    • ESKD: 5.2% versus 7.5% (placebo).
    • Cardiovascular death: 4% versus 5% (placebo).
  • EMPA-KIDNEY trial stopped early for benefit.7,8
  • Guidelines9 recommend metformin and SGLT2i first-line for patients with type-2 diabetes and CKD.
  • Cost: ~$90/month.10

Gilbert Bretecher November 6, 2022

SGLT2i meds appear beneficial in CKD

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Jamie Falk BSc(Pharm) PharmD
  • Scott Klarenbach MD FRCPC
  • Cynthia Lam PharmD ACPR
  • Jennifer Potter MD CCFP

1. Palmer SC, Tendal B, Mustafa RA, et al. BMJ. 2021; 372:m4573.

2. Kaze AD, Zhuo M, Kim SC, et al. Cardiovasc Diabetol. 2022; 21:47.

3. Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019; 380:2295-2306.

4. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. N Engl J Med. 2020; 383:1436-1446.

5. Bhatt DL, Szarek M, PittB, et al. N Engl J Med. 2021; 384:129-39.

6. Patoulias D, Papdopoulos C, Stavropoulos K, et al. Am J Cardiol. 2021; 138:116-132.

7. [accessed 2022 June 15].

8. Boehringer Ingelheim [accessed 2022 June 15].

9. de Boer IH, Caramori ML, Chan JCN, et al. Kidney Int. 2020; 98:839–848.

10. PEER/Alberta College of Family Physicians Price Comparison of Commonly Prescribed Pharmaceuticals in Alberta 2022. Available at: [accessed 2022 Jun 21].

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.